Abstract
Advances in immunotherapy, targeted therapy, and biomarker-driven treatment strategies are transforming the management of resectable non–small cell lung cancer (NSCLC). During JADPRO Live 2024, presenters discussed the latest advancements in perioperative and adjuvant therapies, biomarker testing, and future directions in NSCLC treatment.
